Literature DB >> 2970470

Gamma-atrial natriuretic polypeptide (gamma ANP)-derived peptides in human plasma: cosecretion of N-terminal gamma ANP fragment and alpha ANP.

H Itoh1, K Nakao, A Sugawara, Y Saito, M Mukoyama, N Morii, T Yamada, S Shiono, H Arai, K Hosoda.   

Abstract

Using RIAs for the N- and C-terminal fragments of the human atrial natriuretic polypeptide (ANP) precursor gamma ANP, that is gamma ANP-(1-25), and alpha ANP [gamma ANP-(99-126)], we studied the secretion of gamma ANP-derived peptides from the heart in normal subjects and patients with heart disease, chronic renal failure, and cirrhosis. We detected gamma ANP-(1-25)-like immunoreactivity (-LI) in plasma from normal subjects (n = 17) in considerable amounts [mean, 510 +/- 62 (+/- SE) pg/mL (174 +/- 21 pmol/L)]; the mean plasma alpha ANP-LI level at the same time in these subjects was 32.8 +/- 4.4 pg/mL (10.7 +/- 1.4 pmol/L). Gel permeation chromatographic analysis of plasma samples from normal subjects and patients with heart disease and chronic renal failure revealed two major components; one was alpha ANP, and the other was the 10K N-terminal gamma ANP fragment (N-peptide) resulting from the removal of alpha ANP (3K) from gamma ANP (13K). In addition, gamma ANP (13K), which possessed both gamma ANP-(1-25)-LI and alpha ANP-LI, and beta ANP, an antiparallel dimer of alpha ANP, were detected in some patients as minor components. A significant positive correlation between plasma levels of the N-terminal gamma ANP fragment and alpha ANP (P less than 0.01) and almost equal step-ups in the coronary sinus plasma levels of the N-terminal gamma ANP fragment and alpha ANP suggest that they are cosecreted in equimolar amounts. The high molar ratio of plasma gamma ANP-(1-25)-LI to alpha ANP-LI (17.4 +/- 1.4) in normal subjects and the significantly higher ratio in patients with chronic renal failure (36.9 +/- 7.1; P less than 0.01) suggest the slower clearance of the N-terminal gamma ANP fragment than alpha ANP and a role for the kidney in its degradation. Since the molar ratio of plasma gamma ANP-(1-25)-LI to alpha ANP-LI in patients with cirrhosis (20.7 +/- 2.7) was similar to that in normal subjects, it is unlikely that the N-terminal gamma ANP fragment is metabolized by the liver. In patients with heart disease, plasma gamma ANP-(1-25)-LI and alpha ANP-LI levels were higher in those with cardiac decompensation and were positively correlated with right atrial pressure, pulmonary arterial pressure, and pulmonary capillary wedge pressure, indicating cosecretion of the N-terminal gamma ANP fragment and alpha ANP in response to atrial stretch.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2970470     DOI: 10.1210/jcem-67-3-429

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure.

Authors:  A Clerico; G Iervasi; M G Del Chicca; M Emdin; S Maffei; M Nannipieri; L Sabatino; F Forini; C Manfredi; L Donato
Journal:  J Endocrinol Invest       Date:  1998-03       Impact factor: 4.256

2.  A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community.

Authors:  Valentina Cannone; Guido Boerrigter; Alessandro Cataliotti; Lisa C Costello-Boerrigter; Timothy M Olson; Paul M McKie; Denise M Heublein; Brian D Lahr; Kent R Bailey; Maurizio Averna; Margaret M Redfield; Richard J Rodeheffer; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2011-08-02       Impact factor: 24.094

3.  Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells.

Authors:  H Itoh; R E Pratt; V J Dzau
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

4.  The effects of low dose intravenous 99-126 atrial natriuretic factor infusion in patients with chronic renal failure.

Authors:  A S Woolf; M A Mansell; B I Hoffbrand; S L Cohen; P J Moult
Journal:  Postgrad Med J       Date:  1989-06       Impact factor: 2.401

5.  Chronic blockade of endogenous atrial natriuretic polypeptide (ANP) by monoclonal antibody against ANP accelerates the development of hypertension in spontaneously hypertensive and deoxycorticosterone acetate-salt-hypertensive rats.

Authors:  H Itoh; K Nakao; M Mukoyama; T Yamada; K Hosoda; G Shirakami; N Morii; A Sugawara; Y Saito; S Shiono
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

Review 6.  Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics.

Authors:  A C Tan; F G Russel; T Thien; T J Benraad
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

7.  Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation.

Authors:  T Omland; V V Bonarjee; D W Nilsen; J A Sundsfjord; R T Lie; G Thibault; K Dickstein
Journal:  Br Heart J       Date:  1993-11

8.  Glucose transporter (GLUT-4) is targeted to secretory granules in rat atrial cardiomyocytes.

Authors:  J W Slot; G Garruti; S Martin; V Oorschot; G Posthuma; E W Kraegen; R Laybutt; G Thibault; D E James
Journal:  J Cell Biol       Date:  1997-06-16       Impact factor: 10.539

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.